|
HUE035389T2
(en)
|
2006-09-26 |
2018-05-02 |
Celgene Corp |
5-substituted quinazolinone derivatives as anticancer agents
|
|
KR100987051B1
(ko)
*
|
2008-12-23 |
2010-10-11 |
한국수력원자력 주식회사 |
입자추적법을 이용한 복잡흐름장에서의 오염 물질 이동 수치모사 방법
|
|
RU2611007C2
(ru)
|
2011-03-11 |
2017-02-17 |
Селджин Корпорейшн |
Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2014039421A1
(en)
|
2012-09-04 |
2014-03-13 |
Celgene Corporation |
Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
WO2014121033A1
(en)
|
2013-02-04 |
2014-08-07 |
Fl Therapeutics Llc |
Soluble complexes of drug analogs and albumin
|
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3964507A1
(en)
|
2013-10-04 |
2022-03-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
|
EP4649963A3
(en)
*
|
2014-04-14 |
2026-05-13 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
*
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN106456699B
(zh)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
|
|
US9937259B2
(en)
|
2014-06-27 |
2018-04-10 |
Zhuhai Beihai Biotech Co., Ltd. |
Abiraterone derivatives and non-covalent complexes with albumin
|
|
CA2955972A1
(en)
|
2014-07-22 |
2016-01-28 |
Bioventures, Llc. |
Compositions and methods for selectively depleting senescent cells
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
WO2016065139A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Fl Therapeutics Llc |
3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
*
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
AU2016232705C1
(en)
|
2015-03-18 |
2021-06-17 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
GB201506871D0
(en)
*
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CA2988414C
(en)
*
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
EP3337476A4
(en)
*
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
WO2017040304A1
(en)
|
2015-08-28 |
2017-03-09 |
Cornell University |
Malt1 inhibitors and uses thereof
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
WO2017117473A1
(en)
*
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
|
WO2017117474A1
(en)
*
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
CA3014644A1
(en)
|
2016-02-15 |
2017-08-24 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
|
|
CN109153644B
(zh)
|
2016-03-16 |
2022-10-21 |
H·李·莫菲特癌症中心研究有限公司 |
用以增强效应t细胞功能的针对cereblon的小分子
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
EP3440082A1
(en)
*
|
2016-04-06 |
2019-02-13 |
The Regents of The University of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
AU2017246452C1
(en)
*
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
AU2017250076B2
(en)
*
|
2016-04-12 |
2021-07-22 |
The Regents Of The University Of Michigan |
Bet protein degraders
|
|
CN109152933B
(zh)
*
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
|
WO2017185036A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
WO2017185031A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
AU2017254702B2
(en)
*
|
2016-04-22 |
2020-12-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
|
|
US10865205B2
(en)
|
2016-04-22 |
2020-12-15 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197046A1
(en)
*
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
CN109414596B
(zh)
|
2016-05-12 |
2023-09-29 |
密歇根大学董事会 |
Ash1l抑制剂和用其进行治疗的方法
|
|
CN109152843A
(zh)
|
2016-05-20 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
GB201610156D0
(en)
|
2016-06-10 |
2016-07-27 |
Otsuka Pharma Co Ltd |
Cliptac compositions
|
|
AU2017281525B2
(en)
*
|
2016-06-23 |
2021-01-21 |
Dana-Farber Cancer Institute, Inc. |
Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use
|
|
US11285218B2
(en)
|
2016-06-23 |
2022-03-29 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
|
|
GB201614134D0
(en)
*
|
2016-08-18 |
2016-10-05 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CA3036834A1
(en)
*
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as bet protein degraders
|
|
ES2857743T3
(es)
*
|
2016-09-13 |
2021-09-29 |
Univ Michigan Regents |
1,4-diazepinas fusionadas como degradadores de proteína BET
|
|
GB2554071A
(en)
*
|
2016-09-14 |
2018-03-28 |
Univ Dundee |
Small molecules
|
|
EP3512842B1
(en)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
SI3526202T1
(sl)
|
2016-10-11 |
2025-04-30 |
Arvinas Operations, Inc. |
Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
|
|
CN109983027A
(zh)
*
|
2016-10-20 |
2019-07-05 |
细胞基因公司 |
基于cereblon的可异二聚化嵌合抗原受体
|
|
EP3530652A4
(en)
*
|
2016-10-21 |
2020-03-25 |
Keio University |
MODIFIED PHENYLPHTHALIMIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
|
|
MX2019004950A
(es)
|
2016-10-28 |
2019-09-26 |
Icahn School Med Mount Sinai |
Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
|
|
MX2019005007A
(es)
*
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
US10689366B2
(en)
|
2016-11-01 |
2020-06-23 |
Cornell University |
Compounds for MALT1 degredation
|
|
AU2017363257B2
(en)
*
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
US10842878B2
(en)
*
|
2016-11-22 |
2020-11-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
CA3045037A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
IL325835A
(en)
*
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
*
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
*
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
CN107056772A
(zh)
*
|
2017-01-23 |
2017-08-18 |
中国药科大学 |
基于cereblon配体诱导BET降解的双功能分子及其制备和应用
|
|
IL300417A
(en)
*
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
IL319363A
(en)
*
|
2017-01-31 |
2025-05-01 |
Arvinas Operations Inc |
Cervalon ligands and bifunctional compounds containing them
|
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
JP6773915B2
(ja)
*
|
2017-02-13 |
2020-10-21 |
カング バイオファーマシューティカルズ リミテッド |
前立腺癌を治療する組み合わせ、薬物組成物および治療方法
|
|
CN110573507B
(zh)
*
|
2017-04-14 |
2023-11-14 |
邓迪大学 |
小分子
|
|
CN107033147B
(zh)
*
|
2017-04-25 |
2018-08-21 |
东南大学 |
一种bet/hdac双靶点抑制剂及其制备方法和应用
|
|
WO2018200981A1
(en)
*
|
2017-04-28 |
2018-11-01 |
Quartz Therapeutics, Inc. |
Raf-degrading conjugate compounds
|
|
CN108947888B
(zh)
*
|
2017-05-23 |
2021-05-07 |
南京理工大学 |
一种在水相中钯催化合成3-取代异吲哚啉酮的方法
|
|
EP4717317A3
(en)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
US10716858B2
(en)
|
2017-06-30 |
2020-07-21 |
Massachusetts Institute Of Technology |
Branched multi-functional macromonomers and uses thereof
|
|
GB201710620D0
(en)
*
|
2017-07-03 |
2017-08-16 |
Glaxosmithkline Intellectual Property Ltd |
Targeted protein degradation
|
|
US20210154184A1
(en)
*
|
2017-07-12 |
2021-05-27 |
Dana-Farber Cancer Institute, Inc. |
Compounds for tau protein degradation
|
|
WO2019023553A1
(en)
*
|
2017-07-28 |
2019-01-31 |
Arvinas, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR
|
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
CN109422751B
(zh)
*
|
2017-09-03 |
2022-04-22 |
上海美志医药科技有限公司 |
一类具有降解酪氨酸蛋白激酶jak3活性的化合物
|
|
CN109422733A
(zh)
*
|
2017-09-03 |
2019-03-05 |
上海美志医药科技有限公司 |
一类抑制并降解酪氨酸蛋白激酶alk的化合物
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
SG11202003415XA
(en)
*
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EP3676268A1
(en)
*
|
2017-10-20 |
2020-07-08 |
Dana-Farber Cancer Institute, Inc. |
Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
|
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
US10632209B2
(en)
*
|
2017-11-10 |
2020-04-28 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019109415A1
(zh)
*
|
2017-12-04 |
2019-06-13 |
清华大学 |
一种靶向降解hmgcr的化合物及其应用
|
|
EP3724180B1
(en)
|
2017-12-13 |
2023-02-22 |
Dana-Farber Cancer Institute, Inc. |
Compounds for the degradation of stk4 and treatment of hematologic malignancies
|
|
WO2019114770A1
(zh)
*
|
2017-12-13 |
2019-06-20 |
上海科技大学 |
Alk蛋白降解剂及其抗肿瘤应用
|
|
CN111491933A
(zh)
|
2017-12-18 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
具有e3泛素连接酶部分的egfr双功能抑制剂
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
CN119792569A
(zh)
*
|
2018-01-10 |
2025-04-11 |
财团法人生物技术开发中心 |
抗体protac偶联物
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
ES3041854T3
(en)
|
2018-01-22 |
2025-11-17 |
Bioventures Llc |
Bcl-2 proteins degraders for cancer treatment
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
TW201945357A
(zh)
|
2018-02-05 |
2019-12-01 |
瑞士商赫孚孟拉羅股份公司 |
化合物
|
|
US11702402B2
(en)
*
|
2018-02-23 |
2023-07-18 |
Dana-Farber Cancer Institute, Inc. |
Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof
|
|
JP2021515013A
(ja)
|
2018-03-06 |
2021-06-17 |
アイカーン スクール オブ メディスン アット マウント シナイ |
セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
|
|
WO2019170150A1
(zh)
|
2018-03-09 |
2019-09-12 |
上海科技大学 |
蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
|
|
WO2019177902A1
(en)
|
2018-03-10 |
2019-09-19 |
Yale University |
Modulators of btk proteolysis and methods of use
|
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
|
CN111902141A
(zh)
*
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
|
CN110317192A
(zh)
*
|
2018-03-28 |
2019-10-11 |
上海美志医药科技有限公司 |
一类具有降解雄激素受体活性的化合物
|
|
AU2019249849C1
(en)
*
|
2018-04-01 |
2022-09-29 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
EP3778590A4
(en)
|
2018-04-09 |
2021-12-22 |
ShanghaiTech University |
ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
|
|
CA3303472A1
(en)
|
2018-04-13 |
2026-05-13 |
Massachusetts Institute Of Technology |
Brush prodrugs and uses thereof
|
|
CA3095912A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
EP3556760A1
(en)
|
2018-04-19 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN111741769B
(zh)
*
|
2018-04-20 |
2022-09-16 |
四川科伦博泰生物医药股份有限公司 |
一种多功能化合物、其制备方法及其在医药上的应用
|
|
WO2019221755A1
(en)
|
2018-05-18 |
2019-11-21 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CA3103185A1
(en)
|
2018-06-13 |
2019-12-19 |
Amphista Therapeutics Ltd |
Bifunctional molecules for targeting rpn11
|
|
JP2021527666A
(ja)
*
|
2018-06-21 |
2021-10-14 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
|
|
AU2019294835B2
(en)
*
|
2018-06-29 |
2025-04-17 |
Dana-Farber Cancer Institute, Inc. |
Ligands to cereblon (CRBN)
|
|
CN110372693B
(zh)
*
|
2018-07-04 |
2022-05-03 |
清华大学 |
一种靶向降解bet蛋白的化合物及其应用
|
|
WO2020010204A1
(en)
|
2018-07-05 |
2020-01-09 |
Icahn School Of Medicine At Mount Sinai |
Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
|
|
CN108794453A
(zh)
*
|
2018-07-05 |
2018-11-13 |
清华大学 |
一种靶向降解fak蛋白的化合物及其应用
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EP3820532A4
(en)
*
|
2018-07-11 |
2022-04-06 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS
|
|
US12011432B2
(en)
|
2018-07-18 |
2024-06-18 |
Case Western Reserve University |
Method of modulating ribonucleotide reductase
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
MX2021001957A
(es)
*
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
CN119219628A
(zh)
|
2018-09-07 |
2024-12-31 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
|
|
CN111018857B
(zh)
*
|
2018-10-09 |
2023-06-02 |
嘉兴优博生物技术有限公司 |
靶向蛋白酶降解平台(ted)
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
BR112021011968A2
(pt)
|
2018-12-19 |
2021-09-08 |
Celgene Corporation |
Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
|
|
AU2019404022A1
(en)
|
2018-12-19 |
2021-07-08 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
US20220081435A1
(en)
*
|
2019-01-03 |
2022-03-17 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
WO2020160295A1
(en)
*
|
2019-01-30 |
2020-08-06 |
Montelino Therapeutics, Llc |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
JP7394140B2
(ja)
*
|
2019-02-02 |
2023-12-07 |
シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド |
標的ユビキチン化分解ｂｒｄ４タンパク質化合物、その調製方法および応用
|
|
WO2020163170A1
(en)
*
|
2019-02-05 |
2020-08-13 |
The Board Of Regents Of The University Of Texas System |
Trapping-free parp inhibitors
|
|
KR102876423B1
(ko)
*
|
2019-02-07 |
2025-10-24 |
한국화학연구원 |
표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
WO2020176424A1
(en)
*
|
2019-02-25 |
2020-09-03 |
Chdi Foundation, Inc. |
Compounds for targeting mutant huntingtin protein and uses thereof
|
|
EP3932922A4
(en)
|
2019-02-25 |
2022-05-11 |
ShanghaiTech University |
SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
|
|
US12186401B2
(en)
|
2019-03-01 |
2025-01-07 |
Ontario Institute for Cancer Research (OICR) and Sinai Health System |
Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
JP7667742B2
(ja)
|
2019-04-09 |
2025-04-23 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法
|
|
KR102947433B1
(ko)
|
2019-04-12 |
2026-04-06 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
WO2020214555A1
(en)
|
2019-04-16 |
2020-10-22 |
Northwestern University |
Bifunctional compounds comprising apcin-a and their use in the treatment of cancer
|
|
BR112021020775A2
(pt)
*
|
2019-04-18 |
2021-12-14 |
Hinova Pharmaceuticals Inc |
Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos
|
|
CN114423463B
(zh)
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
CR20210587A
(es)
|
2019-05-31 |
2022-02-11 |
Janssen Pharmaceutica Nv |
Inhibidores de molécula pequeña de quinasa inductora de nf-kb
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
EP4029499A4
(en)
|
2019-06-12 |
2023-07-26 |
Shanghaitech University |
Alk protein regulator and anti-tumor application thereof
|
|
WO2020253711A1
(zh)
*
|
2019-06-17 |
2020-12-24 |
中国科学院上海药物研究所 |
一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
|
|
CN110372669B
(zh)
*
|
2019-06-19 |
2020-11-24 |
浙江省医学科学院 |
一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用
|
|
WO2020263989A1
(en)
|
2019-06-24 |
2020-12-30 |
University Of Iowa Research Foundation |
Jnk inhibitors as anticancer agents
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021023233A1
(zh)
|
2019-08-05 |
2021-02-11 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
US12636370B2
(en)
|
2019-08-08 |
2026-05-26 |
Institute For Cancer Research |
Combination therapy for treatment of cancer
|
|
WO2021041348A1
(en)
*
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
CN114761400B
(zh)
*
|
2019-09-12 |
2024-08-13 |
南京明德新药研发有限公司 |
一种可降解蛋白的并环类化合物及其应用
|
|
CN110563703B
(zh)
*
|
2019-09-18 |
2021-04-09 |
浙江省医学科学院 |
基于crbn配体诱导parp-1降解的化合物及制备方法和应用
|
|
EP3795570B1
(en)
*
|
2019-09-23 |
2022-02-23 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
|
|
EP4034114A4
(en)
|
2019-09-23 |
2023-07-26 |
Accutar Biotechnology Inc. |
Novel ureas having androgen receptor degradation activity and uses thereof
|
|
JP7502425B2
(ja)
|
2019-10-01 |
2024-06-18 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
Ｂｒｍ標的化化合物および関連使用方法
|
|
CA3154334A1
(en)
|
2019-10-16 |
2021-04-22 |
Jeremiah A. Johnson |
Brush prodrugs and uses thereof
|
|
MX2022004526A
(es)
*
|
2019-10-17 |
2022-07-21 |
Arvinas Operations Inc |
Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
|
|
US20210113557A1
(en)
*
|
2019-10-22 |
2021-04-22 |
Arvinas Operations, Inc. |
Methods of treating prostate cancer
|
|
CN112707900B
(zh)
*
|
2019-10-24 |
2022-06-10 |
上海科技大学 |
蛋白降解剂及其在疾病治疗中的应用
|
|
CN110713480B
(zh)
*
|
2019-10-28 |
2021-02-26 |
浙江省医学科学院 |
AChE蛋白降解物及其制备方法和应用
|
|
CN110746400B
(zh)
*
|
2019-11-07 |
2021-12-17 |
郑州大学 |
一种靶向雄激素受体的荧光探针及其制备方法
|
|
CN110790750B
(zh)
*
|
2019-11-07 |
2021-09-21 |
郑州大学 |
一种邻苯二甲酰亚胺类选择性雄激素受体降解剂及其制备方法和用途
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220114615A
(ko)
|
2019-12-16 |
2022-08-17 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
Egfr 키나제의 분해를 억제 및 유도하는 화합물
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
US20230099031A1
(en)
*
|
2019-12-17 |
2023-03-30 |
Orionis Biosciences, Inc. |
Bifunctional agents for protein recruitment and/or degradation
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
WO2021127443A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
AU2020414151A1
(en)
|
2019-12-23 |
2022-08-25 |
Jiangxi Jemincare Group Co., Ltd |
Protein degradation agent compound preparation method and application
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
US20230117831A1
(en)
*
|
2020-01-08 |
2023-04-20 |
The Broad Institute, Inc. |
Multi-functional chimeric molecules
|
|
WO2021141662A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Massachusetts Institute Of Technology |
Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
|
|
MX2022009419A
(es)
|
2020-01-31 |
2022-08-25 |
Avilar Therapeutics Inc |
Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
|
|
CN113248484A
(zh)
*
|
2020-02-13 |
2021-08-13 |
上海强睿生物科技有限公司 |
一种特异性降解tau蛋白的小分子化合物及其应用
|
|
KR20210103973A
(ko)
*
|
2020-02-14 |
2021-08-24 |
보로노이 주식회사 |
단백질 키나아제 분해 유도 화합물 및 이의 용도
|
|
JP7815127B2
(ja)
|
2020-02-19 |
2026-02-17 |
ニューリックス セラピューティクス，インコーポレイテッド |
インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用
|
|
BR112022016901A2
(pt)
*
|
2020-02-26 |
2022-12-06 |
Cullgen Shanghai Inc |
Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
|
|
CN115210227A
(zh)
|
2020-03-04 |
2022-10-18 |
基因泰克公司 |
作为tead抑制剂的异双功能分子
|
|
CN119823124A
(zh)
|
2020-03-05 |
2025-04-15 |
C4医药公司 |
用于brd9的靶向降解的化合物
|
|
CN113387930B
(zh)
|
2020-03-11 |
2022-07-12 |
苏州开拓药业股份有限公司 |
一种双官能化合物及其制备方法和用途
|
|
CN115380026B
(zh)
*
|
2020-03-17 |
2023-11-07 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
KR102624481B1
(ko)
*
|
2020-03-20 |
2024-01-16 |
(주)프레이저테라퓨틱스 |
p38 제거능을 갖는 화합물, 이의 제조방법 및 이를 포함하는 만성 염증성 질환 치료용 조성물
|
|
KR20230004511A
(ko)
|
2020-03-21 |
2023-01-06 |
아비나스 오퍼레이션스, 인코포레이티드 |
인다졸계 화합물 및 관련된 사용 방법
|
|
CN115605267B
(zh)
|
2020-03-21 |
2025-07-29 |
阿维纳斯企业公司 |
突变体lrrk2蛋白水解的选择性调节剂和相关使用方法
|
|
US20230158158A1
(en)
|
2020-03-27 |
2023-05-25 |
Uppthera |
Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
|
|
US20220370416A1
(en)
|
2020-04-06 |
2022-11-24 |
Arvinas Operations, Inc. |
Compounds and methods for targeted degradation of kras
|
|
KR102185390B1
(ko)
*
|
2020-04-17 |
2020-12-01 |
(주) 업테라 |
세포 투과성 세레블론 재조합 융합 단백질 및 이의 용도
|
|
WO2021217036A1
(en)
*
|
2020-04-23 |
2021-10-28 |
Salem Aliasger K |
Gper proteolytic targeting chimeras
|
|
ES3014370T3
(en)
*
|
2020-04-28 |
2025-04-22 |
Rhizen Pharmaceuticals Ag |
Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
|
|
WO2021219077A1
(zh)
*
|
2020-04-29 |
2021-11-04 |
泰比棣医药科技(石家庄)有限公司 |
一种组织靶向的蛋白靶向降解化合物及其用途
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
CN115996918A
(zh)
|
2020-05-09 |
2023-04-21 |
阿尔维纳斯运营股份有限公司 |
制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
|
|
GB202007106D0
(en)
|
2020-05-14 |
2020-07-01 |
Ucl Business Plc |
Cyclosporine analogues
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
KR20230024328A
(ko)
|
2020-06-12 |
2023-02-20 |
상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 |
프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
|
|
WO2021255212A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Braf degraders
|
|
CN115916769B
(zh)
*
|
2020-06-28 |
2024-09-10 |
深圳扬厉医药技术有限公司 |
并环吲唑类化合物
|
|
CN114341128B
(zh)
*
|
2020-07-24 |
2024-06-25 |
恩瑞生物医药科技（上海）有限公司 |
双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
|
|
CN116490186B
(zh)
|
2020-08-05 |
2025-10-31 |
C4医药公司 |
用于ret的靶向降解的化合物
|
|
CN114057770B
(zh)
*
|
2020-08-06 |
2023-05-02 |
成都先导药物开发股份有限公司 |
靶向egfr蛋白降解的双功能化合物
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
IL302037A
(en)
*
|
2020-10-14 |
2023-06-01 |
C4 Therapeutics Inc |
Tricyclic heterobifunctional compounds for degradation of targeted proteins
|
|
WO2022087125A1
(en)
|
2020-10-21 |
2022-04-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor protein
|
|
EP4240733A1
(en)
*
|
2020-11-06 |
2023-09-13 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
|
CN112341436A
(zh)
*
|
2020-11-20 |
2021-02-09 |
中国药科大学 |
基于靶向抑制和降解alk的苯并咔唑类蛋白水解靶向嵌合分子、制备方法及用途
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
TW202237095A
(zh)
|
2020-12-03 |
2022-10-01 |
德商艾斯巴赫生物有限公司 |
Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
|
|
CN112480081B
(zh)
*
|
2020-12-07 |
2022-02-22 |
沈阳药科大学 |
一种基于Cereblon配体诱导SHP2蛋白降解的双功能分子化合物
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
US20240124418A1
(en)
*
|
2020-12-14 |
2024-04-18 |
Biotheryx, Inc. |
Pde4 degraders, pharmaceutical compositions, and therapeutic applications
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
WO2022146151A1
(en)
*
|
2020-12-30 |
2022-07-07 |
Captor Therapeutics S.A. |
Novel compounds which bind to cereblon, and methods of use thereof
|
|
US12152035B2
(en)
|
2020-12-30 |
2024-11-26 |
Industrial Technology Research Institute |
Androgen receptor binding molecule and use thereof
|
|
CN117242060B
(zh)
|
2021-01-13 |
2026-07-17 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮化合物
|
|
US12569564B2
(en)
|
2021-01-23 |
2026-03-10 |
Newave Pharmaceutical Inc. |
Spirocyclic MDM2 modulator and uses thereof
|
|
JP2024505562A
(ja)
|
2021-02-02 |
2024-02-06 |
レス ラボラトイレス セルビエル |
選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
|
|
LT4293024T
(lt)
|
2021-02-15 |
2026-05-25 |
Astellas Pharma Inc. |
Chinazolino junginys, skirtas g12d mutantinio kras baltymo degradacijai sukelti
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CA3211347A1
(en)
|
2021-03-19 |
2022-09-22 |
Erika Araujo |
Indazole based compounds and associated methods of use
|
|
CN117321046A
(zh)
*
|
2021-03-19 |
2023-12-29 |
阿维纳斯企业公司 |
基于吲唑的化合物和相关使用方法
|
|
JP2024512544A
(ja)
*
|
2021-03-29 |
2024-03-19 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用
|
|
CN118388454A
(zh)
|
2021-04-16 |
2024-07-26 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
MX2023012981A
(es)
*
|
2021-05-03 |
2024-01-11 |
Nurix Therapeutics Inc |
Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
|
|
AU2022268925A1
(en)
|
2021-05-03 |
2023-11-16 |
Avilar Therapeutics, Inc. |
Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
|
|
US20240287076A1
(en)
|
2021-05-05 |
2024-08-29 |
Biogen Ma Inc. |
Compounds for targeting degradation of bruton's tyrosine kinase
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
BR112023024507A2
(pt)
|
2021-05-26 |
2024-02-15 |
C4 Therapeutics Inc |
Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
|
|
AU2022290851A1
(en)
|
2021-06-08 |
2023-11-23 |
C4 Therapeutics, Inc. |
Therapeutics for the degradation of mutant braf
|
|
WO2022266258A1
(en)
|
2021-06-15 |
2022-12-22 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of irak-4
|
|
CN113481289B
(zh)
*
|
2021-06-22 |
2022-03-29 |
天津见康华美医学诊断技术有限公司 |
一种铁粒幼红细胞性贫血检测引物组合物及应用
|
|
CN113354619B
(zh)
*
|
2021-06-24 |
2024-03-19 |
皖南医学院 |
一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用
|
|
JP2024526259A
(ja)
|
2021-07-02 |
2024-07-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗ｐｒｏｔａｃ抗体および複合体
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
WO2023283372A1
(en)
|
2021-07-07 |
2023-01-12 |
Biogen Ma Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
CA3224732A1
(en)
|
2021-07-07 |
2023-01-12 |
Kevin M. Guckian |
Compounds for targeting degradation of irak4 proteins
|
|
CN113278023B
(zh)
*
|
2021-07-22 |
2021-10-15 |
上海睿跃生物科技有限公司 |
含氮杂环化合物及其制备方法和应用
|
|
EP4384828A4
(en)
*
|
2021-08-12 |
2025-09-17 |
Univ Ramot |
MARKERS OF DISEASE RESISTANCE AND TOLERANCE AND THEIR USES
|
|
HUE070709T2
(hu)
|
2021-08-18 |
2025-06-28 |
Nurix Therapeutics Inc |
Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk
|
|
EP4395549A1
(en)
|
2021-09-01 |
2024-07-10 |
Oerth Bio LLC |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115772210A
(zh)
*
|
2021-09-08 |
2023-03-10 |
苏州开拓药业股份有限公司 |
硫代乙内酰脲化合物或其药用盐的无定形物、晶体、药物组合物、制备方法和用途
|
|
WO2023038500A1
(ko)
*
|
2021-09-13 |
2023-03-16 |
주식회사 유빅스테라퓨틱스 |
Enl 단백질 분해용 화합물 및 이들의 의약 용도
|
|
WO2023056443A1
(en)
*
|
2021-10-01 |
2023-04-06 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
KR20240111312A
(ko)
|
2021-10-25 |
2024-07-16 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Tyk2 분해제 및 이의 용도
|
|
WO2023074780A1
(ja)
*
|
2021-10-27 |
2023-05-04 |
国立大学法人愛媛大学 |
治療薬組成物
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
JP2024541479A
(ja)
|
2021-11-24 |
2024-11-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｂｒｍ標的化化合物及び関連使用方法
|
|
CN118679160A
(zh)
|
2021-11-24 |
2024-09-20 |
阿维纳斯运营公司 |
Brm靶向化合物和相关的使用方法
|
|
WO2023093845A1
(zh)
|
2021-11-25 |
2023-06-01 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
WO2023121753A1
(en)
|
2021-12-20 |
2023-06-29 |
Massachusetts Institute Of Technology |
Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent
|
|
WO2023119677A1
(en)
|
2021-12-24 |
2023-06-29 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising a quinazoline compound
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
CN114410773B
(zh)
*
|
2022-01-27 |
2024-05-03 |
宁波大学 |
用于预测或诊断抑郁症复发的标志物组合及其应用
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
CA3255513A1
(en)
|
2022-03-11 |
2025-03-04 |
Astellas Pharma Inc. |
HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
|
|
CN114907386B
(zh)
*
|
2022-03-11 |
2023-03-31 |
山东大学 |
一种hemtac小分子降解剂及其应用
|
|
CN114560908B
(zh)
*
|
2022-03-11 |
2024-10-25 |
国家纳米科学中心 |
一种多肽protac分子及其制备方法和应用
|
|
CN116789636B
(zh)
*
|
2022-03-14 |
2026-01-30 |
北京康辰药业股份有限公司 |
双功能化合物及其制备方法、药物组合物和用途
|
|
CN119301111A
(zh)
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
EP4511128A1
(en)
|
2022-04-20 |
2025-02-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
US20240050577A1
(en)
*
|
2022-04-27 |
2024-02-15 |
Risen (Suzhou) Pharma Tech Co., Ltd. |
Cdk inhibitors and pharmaceutical uses thereof
|
|
CN119365198A
(zh)
|
2022-05-02 |
2025-01-24 |
艾斯巴赫生物有限公司 |
ALC1抑制剂的用途和与PARPi的协同作用
|
|
US20260014260A1
(en)
*
|
2022-05-24 |
2026-01-15 |
Newave Pharmaceutical Inc. |
Mdm2 degrader
|
|
IL316803A
(en)
|
2022-06-06 |
2025-01-01 |
C4 Therapeutics Inc |
Bicyclic glutarimide-modified cervalon-binding agents
|
|
WO2024006776A1
(en)
|
2022-06-27 |
2024-01-04 |
Relay Therapeutics, Inc. |
Estrogen receptor alpha degraders and medical use thereof
|
|
CA3260847A1
(en)
|
2022-06-27 |
2024-01-04 |
Relay Therapeutics, Inc. |
Estrogen Alpha Receptor Degrading Agents and Their Uses
|
|
WO2024002205A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same
|
|
WO2024020221A1
(en)
|
2022-07-21 |
2024-01-25 |
Arvinas Operations, Inc. |
Modulators of tyk2 proteolysis and associated methods of use
|
|
WO2024019103A1
(ja)
*
|
2022-07-21 |
2024-01-25 |
アステラス製薬株式会社 |
Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物
|
|
TW202415653A
(zh)
*
|
2022-08-02 |
2024-04-16 |
大陸商北京星奇原生物科技有限公司 |
Ｂｃｌ－ｘｌ降解化合物
|
|
TW202412789A
(zh)
|
2022-08-05 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
用於誘導突變kras蛋白分解之雜環化合物
|
|
WO2024035780A1
(en)
*
|
2022-08-09 |
2024-02-15 |
Board Of Regents Of The University Of Nebraska |
Akr1c3 targeted heterobifunctional small molecule proteolysis targeting chimeras
|
|
CN119604495A
(zh)
|
2022-08-09 |
2025-03-11 |
安斯泰来制药株式会社 |
用于诱导g12v突变kras蛋白分解的杂环化合物
|
|
EP4568674A1
(en)
|
2022-08-12 |
2025-06-18 |
Astellas Pharma Inc. |
Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
|
|
AU2023322690A1
(en)
|
2022-08-12 |
2025-03-20 |
Astellas Pharma Inc. |
Anti cancer combinations comprising chemotherapy
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024064358A1
(en)
|
2022-09-23 |
2024-03-28 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
WO2024073507A1
(en)
|
2022-09-28 |
2024-04-04 |
Theseus Pharmaceuticals, Inc. |
Macrocyclic compounds and uses thereof
|
|
JP2025533592A
(ja)
*
|
2022-09-29 |
2025-10-07 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
テトラリン系誘導体の薬学的に許容される塩、結晶型及び調製方法
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
KR20250079173A
(ko)
|
2022-10-03 |
2025-06-04 |
고리츠다이가쿠호진 요코하마시리츠다이가쿠 |
이환성 구조를 갖는 이미다조피리딘 유도체
|
|
EP4428134A1
(en)
|
2023-03-10 |
2024-09-11 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
IL321713A
(en)
|
2022-12-27 |
2025-08-01 |
Merck Patent Gmbh |
Anti-PROTAC VHH antibodies and complexes
|
|
IL321942A
(en)
|
2023-01-09 |
2025-09-01 |
Arvinas Operations Inc |
Modulators of BCL6 proteolysis and related methods of use
|
|
CN120530094A
(zh)
|
2023-01-12 |
2025-08-22 |
田边三菱制药株式会社 |
Cereblon E3连接酶结合化合物、包含其的药物组合物及其制造方法
|
|
CN120569372A
(zh)
|
2023-01-24 |
2025-08-29 |
第一三共株式会社 |
经取代的苯化合物
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
WO2024178348A2
(en)
|
2023-02-24 |
2024-08-29 |
Ppm Biopharma Llc |
Pleiotropic pathway modifier compounds and method of treating diseases
|
|
CN116854667A
(zh)
*
|
2023-05-17 |
2023-10-10 |
浙江工业大学 |
一种靶向降解pd-l1的蛋白水解靶向嵌合体及其应用
|
|
JP2026519279A
(ja)
*
|
2023-05-18 |
2026-06-15 |
アジュ ユニバーシティー インダストリー－アカデミック コーオペレイション ファウンデーション |
骨分化誘導可能な新規化合物
|
|
WO2024240078A1
(en)
*
|
2023-05-19 |
2024-11-28 |
The Chinese University Of Hong Kong |
Compositions and methods related to protein labeling
|
|
WO2024240858A1
(en)
|
2023-05-23 |
2024-11-28 |
Valerio Therapeutics |
Protac molecules directed against dna damage repair system and uses thereof
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AR133028A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un degradador de todas las kras
|
|
AR133027A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un compuesto de quinazolina
|
|
CN122206684A
(zh)
|
2023-06-30 |
2026-06-12 |
默克专利有限公司 |
用于kras蛋白降解的异双功能化合物
|
|
JP2026524477A
(ja)
|
2023-06-30 |
2026-07-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｋｒａｓの分解のためのヘテロ二官能性化合物
|
|
EP4735451A1
(en)
|
2023-06-30 |
2026-05-06 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
CN117263865B
(zh)
*
|
2023-08-04 |
2026-03-27 |
南开大学 |
以6,6-二甲基双环[3.1.1]-2-甲胺为疏水基团的蛋白降解剂及其制备方法、药物组合物和应用
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
GB202314126D0
(en)
|
2023-09-15 |
2023-11-01 |
Univ Oxford Innovation Ltd |
Compound and method
|
|
AU2024352092A1
(en)
|
2023-09-28 |
2026-04-09 |
Arvinas Operations, Inc. |
Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
|
|
TW202530189A
(zh)
|
2023-09-29 |
2025-08-01 |
日商第一三共股份有限公司 |
３－苯基丙基胺衍生物
|
|
WO2025085738A1
(en)
|
2023-10-18 |
2025-04-24 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
CN122228262A
(zh)
|
2023-11-02 |
2026-06-16 |
金橘生物科技公司 |
降解剂及其用途
|
|
AU2024392985A1
(en)
|
2023-12-08 |
2026-06-04 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|
|
CN122555560A
(zh)
|
2023-12-21 |
2026-08-11 |
丹娜-法伯癌症研究院 |
激酶抑制和降解
|
|
WO2025184594A1
(en)
|
2024-02-29 |
2025-09-04 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
WO2025189056A1
(en)
|
2024-03-08 |
2025-09-12 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|
|
WO2025213104A1
(en)
|
2024-04-05 |
2025-10-09 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of bcl6
|
|
CN118161490B
(zh)
*
|
2024-05-10 |
2024-07-23 |
昆明医科大学 |
一种去泛素化酶抑制剂在制备预防或者治疗炎症药物中的应用
|
|
WO2025262295A1
(en)
|
2024-06-21 |
2025-12-26 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
EP4667467A1
(en)
|
2024-06-21 |
2025-12-24 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
EP4667466A1
(en)
|
2024-06-21 |
2025-12-24 |
Dark Blue Therapeutics Ltd |
Protac degraders of mllt1 and/or mllt3
|
|
CN118459478B
(zh)
*
|
2024-07-09 |
2024-10-29 |
深圳大学 |
一种brd4蛋白靶向降解剂及其制备方法与应用
|
|
WO2026107062A1
(en)
|
2024-11-13 |
2026-05-21 |
Recludix Pharma, Inc. |
Stat6 degraders and uses thereof
|
|
WO2026117543A1
(en)
|
2024-11-26 |
2026-06-04 |
Arvinas Operations, Inc. |
Combination therapy for the targeted degradation of bcl6
|
|
WO2026117542A1
(en)
|
2024-11-26 |
2026-06-04 |
Arvinas Operations, Inc. |
Combination therapy for the targeted degradation of bcl6
|
|
WO2026136623A1
(en)
|
2024-12-19 |
2026-06-25 |
Genentech, Inc. |
Ire1 degrader compounds and methods of use
|
|
WO2026129303A1
(zh)
*
|
2024-12-20 |
2026-06-25 |
上海壹迪生物技术有限公司 |
一种靶向雄激素受体蛋白降解的双功能化合物及其应用
|
|
WO2026139448A1
(en)
|
2024-12-23 |
2026-07-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
CN120154610B
(zh)
*
|
2025-05-19 |
2025-09-02 |
深圳大学 |
抗血栓小分子化合物bptu作为黏菌素佐剂协同抗革兰氏阴性菌的应用
|
|
CN121895289A
(zh)
*
|
2026-03-23 |
2026-04-21 |
四川大学 |
一种哌啶-2,6-二酮类化合物、药物组合物及其制备方法和用途
|
|
CN122234044A
(zh)
*
|
2026-05-14 |
2026-06-19 |
四川大学华西医院 |
靶向乳酸脱氢酶的protac化合物及其制备方法和应用
|